GJE recognised by The Legal 500

We are delighted to be recognised by The Legal 500 as a leading firm in the 2017 rankings. The Legal 500 provide a comprehensive worldwide review of the best and most recommended law firms and attorneys. The rankings are based on the practice area teams who are providing the most cutting edge...

Read more

Changes for UK registered design owners up to the mark

It is important that UK registered design owners mark their associated products in order to inform third parties of their registered design rights. Not only does this deter would-be infringers, but also helps to prevent “innocent infringement”. Under the UK Registered Designs Act, damages will not be awarded in infringement...

Read more

GJE’s oppositions team successfully argue for revocation of patent covering cancer treatment drug

Eisai Lenvima patent revoked by the EPO. On 26th September 2017, Arnie Clarke was representing one of two opponents to successfully seek revocation of EP2036557 at the European Patent Office (EPO). The EPO revoked the patent on the basis that the claims lacked an inventive step. The parent concerned Lenvima, known chemically...

Read more

GJE client Lundbeckfonden Emerge invests €2.6 million in SNIPR Biome Limited

On August 25 2017, Lundbeckfonden Emerge announced the completion of a €2.6 million investment in SNIPR Biome Limited. SNIPR Biome is pioneering its proprietary CRISPR technology to revolutionise the treatment of microbial diseases. The constructs developed by SNIPR can subvert elements of the endogenous bacterial CRISPR machinery to targetedly eliminate...

Read more

Teva Pharmaceutical Industries’ European Patent EP 2361924 revoked

On 12th September 2017, Teva Pharmaceutical Industries’ European Patent EP 2361924 was revoked. The patent was one of a family of patents covering Copaxone® (glatiramer acetate injection), its intermediates and processes for its production. Global Copaxone® franchise sales were $4.1 billion in 2016. The opposition was filed by Mylan, Synthon BV,...

Read more